Explore the Value of Adding Induction Chemotherapy to Concurrent Chemoradiotherapy in T3-4N0M0 Nasopharyngeal Carcinoma Patients: A Retrospective Study

References

• BrayF, FerlayJ, SoerjomataramI. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• ChenYP, ChanATC, LeQT, BlanchardP, SunY, MaJ. Nasopharyngeal carcinoma. Lancet. 2019;394(10192):64–80. doi:10.1016/S0140-6736(19)30956-031178151
   PubMed Web of Science ®Google Scholar
• SunY, LiWF, ChenNY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016;17(11):1509–1520. doi:10.1016/S1470-2045(16)30410-727686945
   PubMed Web of Science ®Google Scholar
• LiWF, ChenNY, ZhangN, et al. Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: long-term results of phase 3 randomized controlled trial. Int J Cancer. 2019;145(1):295–305. doi:10.1002/ijc.3209930613964
   PubMed Web of Science ®Google Scholar
• CaoSM, YangQ, GuoL, et al. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase III multicentre randomised controlled trial. Eur J Cancer. 2017;75:14–23. doi:10.1016/j.ejca.2016.12.03928214653
   PubMed Web of Science ®Google Scholar
• YangQ, CaoSM, GuoL, et al. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial. Eur J Cancer. 2019;119:87–96. doi:10.1016/j.ejca.2019.07.00731425966
   PubMed Web of Science ®Google Scholar
• ZhangY, ChenL, HuGQ, et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med. 2019;381(12):1124–1135. doi:10.1056/NEJMoa190528731150573
   PubMed Web of Science ®Google Scholar
• PfisterDG, SpencerS, AdelsteinD, et al. NCCN clinical practice guidelines: head and neck cancers.Version 3.2021. Natl Compr Cancer Netw. 2021.
   Web of Science ®Google Scholar
• JinT, ZhangQ, LuoD-H, et al. Concurrent chemoradiotherapy with or without induction chemotherapy for patients with stage II nasopharyngeal carcinoma: an update. Transl Oncol. 2020;13(1):25–31. doi:10.1016/j.tranon.2019.08.00731743830
   PubMed Web of Science ®Google Scholar
• YuZ, LuoW, ZhouQC, ZhangQH, KangDH, LiuMZ. Impact of changing gross tumor volume delineation of intensity-modulated radiotherapy on the dose distribution and clinical treatment outcome after induction chemotherapy for the primary locoregionally advanced nasopharyngeal carcinoma. Ai Zheng. 2009;28(11):1132–1137. Chinese.19895731
   PubMedGoogle Scholar
• LinS, LuJ, HanL, ChenQ, PanJ. Sequential chemotherapy and intensity-modulated radiation therapy in the management of locoregionally advanced nasopharyngeal carcinoma: experience of 370 consecutive cases. BMC Cancer. 2010;10(1):39. doi:10.1186/1471-2407-10-3920146823
   PubMed Web of Science ®Google Scholar
• LeeAWM, LauKY, HungWM, et al. Potential improvement of tumor control probability by induction chemotherapy for advanced nasopharyngeal carcinoma. Radiother Oncol. 2008;87(2):204–210. doi:10.1016/j.radonc.2008.02.00318329742
   PubMed Web of Science ®Google Scholar
• LiPJ, MoHY, LuoDH, HuWH, JinT. The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era. Oral Oncol. 2018;85(September):95–100. doi:10.1016/j.oraloncology.2018.08.01630220326
   PubMed Web of Science ®Google Scholar
• ZhangMX, LiJ, ShenGP, et al. Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: a 10-year experience with a large cohort and long follow-up. Eur J Cancer. 2015;51(17):2587–2595. doi:10.1016/j.ejca.2015.08.00626318726
   PubMed Web of Science ®Google Scholar
• LeeAWM, NgWT, ChanLLK, et al. Evolution of treatment for nasopharyngeal cancer - success and setback in the intensity-modulated radiotherapy era. Radiother Oncol. 2014;110(3):377–384. doi:10.1016/j.radonc.2014.02.00324630534
   PubMed Web of Science ®Google Scholar
• OhnoT, WakatsukiM, ThinhDHQ, et al. Concurrent chemoradiotherapy for T3-4 and N0-1 nasopharyngeal cancer: Asian multicenter trial of the Forum for Nuclear Cooperation in Asia. J Radiat Res. 2016;57(1):44–49. doi:10.1093/jrr/rrv04626254458
   PubMed Web of Science ®Google Scholar
• SunJD, ChenCZ, ChenJZ, et al. Long term outcomes and prognostic factors of n0 stage nasopharyngeal carcinoma: a single institutional experience with 610 patients. Asian Pac J Cancer Prev. 2012;13(5):2101–2107. doi:10.7314/APJCP.2012.13.5.210122901177
   PubMedGoogle Scholar
• PengH, ChenL, GuoR, et al. Clinical treatment considerations in the intensity-modulated radiotherapy era for patients with N0-category nasopharyngeal carcinoma and enlarged neck lymph nodes. Chin J Cancer. 2017;36(1):32. doi:10.1186/s40880-017-0199-228340596
   PubMedGoogle Scholar
• WuLR, YuHL, JiangN, et al. Prognostic value of chemotherapy in addition to concurrent chemoradiotherapy in T3-4N0-1 nasopharyngeal carcinoma: a propensity score matching study. Oncotarget. 2017;8(44):76807–76815. doi:10.18632/oncotarget.2001429100350
   PubMedGoogle Scholar
• SunY, TangLL, ChenL, et al. Promising treatment outcomes of intensity-modulated radiation therapy for nasopharyngeal carcinoma patients with N0 disease according to the seventh edition of the AJCC staging system. BMC Cancer. 2012;12:1–8. doi:10.1186/1471-2407-12-6822212211
   PubMed Web of Science ®Google Scholar
• SuSF, HanF, ZhaoC, et al. Treatment outcomes for different subgroups of nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy. Chin J Cancer. 2011;30(8):565–573. doi:10.5732/cjc.010.1054721801605
   PubMedGoogle Scholar
• ZhangF, ZhangY, LiWF, et al. Efficacy of concurrent chemotherapy for intermediate risk NPC in the intensity-modulated radiotherapy era: a propensity-matched analysis. Sci Rep. 2015;5:17378. doi:10.1038/srep1737826611462
   PubMed Web of Science ®Google Scholar
• ChanATC, TeoPML, LeungTWT, et al. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 1995;33(3):569–577. doi:10.1016/0360-3016(95)00218-N7558945
   PubMed Web of Science ®Google Scholar
• ChuaDTT, ShamJST, ChoyD, et al. Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Cancer. 1998;83(11):2270–2283. doi:10.1002/(SICI)1097-0142(19981201)83:11<2270::AID-CNCR6>3.0.CO;2-T9840526
   PubMed Web of Science ®Google Scholar
• TannockIF. Combined modality treatment with radiotherapy and chemotherapy. Radiother Oncol. 1989;16(2):83–101. doi:10.1016/0167-8140(89)90025-X2687956
   PubMed Web of Science ®Google Scholar
• CaoC, LuoJ, GaoL, et al. Concurrent chemotherapy for T4 classification nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy. PLoS One. 2015;10(3):e0119101. doi:10.1371/journal.pone.011910125747589
   PubMed Web of Science ®Google Scholar
• LuoY, GaoY, YangG, LangJ. Clinical outcome and prognostic factors of intensity-modulated radiotherapy for T4 stage nasopharyngeal carcinoma. Biomed Res Int. 2016;2016. doi:10.1155/2016/4398498
   Web of Science ®Google Scholar
• ZhangS, HuangX, ZhouL, LinS. Efficacy of concurrent chemoradiotherapy combined with nimotuzumab for low-risk T4 stage nasopharyngeal carcinoma: a pilot study. Medicine. 2018;97(38):e12503. doi:10.1097/MD.000000000001250330235761
   PubMed Web of Science ®Google Scholar